A preliminary investigation:screening of serum protein markers by protein microarray technology in acute myeloid leukemia
ZHU Lidan,KONG Peiyan,ZHANG Xi,PENG Xiangui,LI Jieping,ZENG Dongfeng,QIANG Xing,DENG Xiaojuan
DOI: https://doi.org/10.13303/j.cjbt.issn.1004-549x.2013.03.039
2013-01-01
Abstract:Objective To screen serum biomarkers in patients with acute myeloid leukemia(AML) using biotin label-based antibody array,that can be applied to AML in its early diagnosis,conditions and prognosis.Methods Biotin label-based antibody array were used to detect 16 serum,including 11 AML of different cytogenetic and molecular biology,and 5 healthy controls.Using microarray analysis software to extract the data,the results obtained were analyzed by AAH-BLG-1 data analysis software.Results Compared with the control group,growth factor including MFG-E8,osteoactivin,Hepassocin,M-CSF,M-CSF R,Insulin R,and interleukin including IL-20,IL-3,IL-1 F8,IL-2 R alpha,IL-2 R beta,IL-1 R6,apoptosis including Fas,adhesis including ICAM-3,chemokine including CCL21,atherosclerosis including Lipocalin-1,Transmembrane protein TMEFF1,matrix metalloproteinase including MMP-3,TNFRSF including GFR alpha-4,TNF-alpha,TNFRF18,TNFRSF21 were all increased significantly(P<0.05).Poor prognosis group compared with the good prognosis group,interleukin including IL-17RD,growth factor including VEGF-D,IGFBP1,matrix metalloproteinase including TIMP-2,angiogensis including Endostatin,Proteolytic enzymes uPA,chemokine MIP-2,FGF-19,binding protein including LBP,adhesis including L-selectin,atherosclerosis SAA(P<0.05)were all increased significantly.Conclusion A total of 33 serum biomarkers in patients with AML were screened using biotin label-based antibody array.Confirmed their participation in the AML cell chemotaxis,adhesion,migration,degradation of the matrix,and malignant proliferation,anti-apoptotic process,can be helpful to a better judgment of the patients′prognosis as well as guiding individual.